Skip to content
MARKETS / NASDAQ / AMRX
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Amneal Pharmaceuticals, Inc. AMRX

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$3.0B
▲ 8.0% YoY
$72.1M
$269.9M
▲ 11.0% YoY
In brief

What this company does

It operates principally in the United States, India, and Ireland. For the year ended December 31, 2025, its four largest customers, Cencora, Inc., McKesson Drug Co., Cardinal Health, Inc., and CVS Health Corporation, collectively accounted for approximately 71% of its consolidated net revenue. It has approximately 1,300 customers in total, including more than 1,100 within its AvKARE segment. It has three reportable segments: Affordable Medicines, Specialty, and AvKARE.

Written from the business description in Amneal Pharmaceuticals, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.

Growth
USD 3.0B
Revenue, FY2025 · full 10-year series below
Revenue $B Net income $B
FY2025 · Revenue 3.0 · Net income 0.1
2.00B-0.25B-0.50B2016201720182019202020212022202320242025
Compound annual growth
+10.9%
+8.7%
+1.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +8.7% a year over five years — but profit grew slower: net income at +1.2%.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
4 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 13.1% · Net 4.2%
10%20%-10%-20%-30%2016201720182019202020212022202320242025
ROE
FY2023 · ROE -52.8%
10%20%-50%-100%-150%2016201720182019202020212022202320242025

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 269.9
200M-20M-40M2016201720182019202020212022202320242025
Net buybacks $M Dividends $M
FY2020 · Dividends 0.0 · Net buybacks —
200M20162017201820192020

Total assetsUSD 3.7B
EquityUSD -70.8M
CashUSD 282.0M
Gross debtUSD 2.6B
Net debtUSD 2.3B
Current ratio2.17×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016
Revenue $B3.02.82.42.22.12.01.61.71.01.0
Operating income $B0.40.20.2−0.10.20.1−0.2−0.00.20.3
EBITDA $B0.50.30.3−0.00.20.2−0.20.00.30.3
Income tax $B0.00.00.00.00.0−0.10.4−0.00.00.0
Net income $B0.1−0.1−0.1−0.30.00.1−0.6−0.00.00.0
Free cash flow $B0.30.20.30.00.20.3−0.00.20.1−0.0
EPS, diluted $0.22−0.38−0.48−0.860.070.61−2.74−0.16··
Dividend / sh $··········
Payout %·····0−0−927··
ROE %··−52.8−82.14.025.3−163.8−7.8··
Shares out B···0.150.15···0.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 3 divergences in 46 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 3 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 49 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures3 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
Data on record since2016

Share this section

Download image